BACKGROUND: To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. METHODS: We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. RESULTS: Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8 ± 7.3 years) were included. Mean follow-up was 20.3 ± 6.2 months. During the first 12 months, patients received 5.5 ± 2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p = 0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p = 0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 μm vs 281.0 ±61.3 μm at baseline, p = 0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27 ± 3.9 mm(2) at baseline vs 4.60 ± 3.5 mm(2) at month 12, p = 0.4), and greatest linear dimension (GLD 2.66 ± 1.2 mm at baseline vs 2.55 ± 1.0 mm at month 12, p = 0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98 ± 3.2 mm2 at baseline vs 4.3 ± 2.7 mm2 at month-12, p = 0.6; GLD 2.11 ± 1.0 mm at baseline vs 2.70 ± 0.8 mm at month-12, p = 0.05). CONCLUSION: ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.
BACKGROUND: To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections. METHODS: We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months. RESULTS: Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8 ± 7.3 years) were included. Mean follow-up was 20.3 ± 6.2 months. During the first 12 months, patients received 5.5 ± 2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters, p = 0.04), and stabilized at 12-month visit (55.7 ±18.2 letters; p = 0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 ±54.7 μm vs 281.0 ±61.3 μm at baseline, p = 0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27 ± 3.9 mm(2) at baseline vs 4.60 ± 3.5 mm(2) at month 12, p = 0.4), and greatest linear dimension (GLD 2.66 ± 1.2 mm at baseline vs 2.55 ± 1.0 mm at month 12, p = 0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98 ± 3.2 mm2 at baseline vs 4.3 ± 2.7 mm2 at month-12, p = 0.6; GLD 2.11 ± 1.0 mm at baseline vs 2.70 ± 0.8 mm at month-12, p = 0.05). CONCLUSION: ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Christopher G Kiss; Wolfgang Geitzenauer; Christian Simader; Giovanni Gregori; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2009-01-10 Impact factor: 4.799
Authors: L A Yannuzzi; M Hope-Ross; J S Slakter; D R Guyer; J A Sorenson; A C Ho; D E Sperber; K B Freund; D A Orlock Journal: Retina Date: 1994 Impact factor: 4.256
Authors: Luiz Roisman; Qinqin Zhang; Ruikang K Wang; Giovanni Gregori; Anqi Zhang; Chieh-Li Chen; Mary K Durbin; Lin An; Paul F Stetson; Gillian Robbins; Andrew Miller; Fang Zheng; Philip J Rosenfeld Journal: Ophthalmology Date: 2016-02-12 Impact factor: 12.079
Authors: Benjamin P Nicholson; Divya Nigam; Brian Toy; Paul F Stetson; Elvira Agrón; Naima Jacobs-El; Denise Cunningham; Catherine Cukras; Wai Wong; Henry Wiley; Emily Chew; Frederick Ferris; Catherine B Meyerle Journal: Retina Date: 2015-01 Impact factor: 4.256
Authors: Scott M McClintic; Simon Gao; Jie Wang; Ahmed Hagag; Andreas K Lauer; Christina J Flaxel; Kavita Bhavsar; Thomas S Hwang; David Huang; Yali Jia; Steven T Bailey Journal: Ophthalmol Retina Date: 2018-03-02